ALX Oncology reported Q4 2025 financial results with improved net losses and announced strong clinical progress for its lead candidates evorpacept and ALX2004. The company validated CD47 as a predictive biomarker for evorpacept response in cancer trials, completed a $150 million equity offering extending cash runway through H1 2028, and appointed Barbara Klencke as permanent Chief Medical Officer. Multiple clinical milestones are anticipated over the next 12-18 months.
ALX Oncology Holdings Inc. Common Stock (ALXO)
Common Stock · Currency in USD · XNAS
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Company Info
SIC2834
Composite FIGIBBG00VR8SDG8
CIK0001810182
IPOJul 17, 2020
Sectorpharmaceutical preparations
Highlights
Market Cap$259.27M
EPS-$1.64
P/E Ratio-2.93
Revenue$NaN
Gross Profit$0.00
Net Income-$88.58M
Employees43
WSO131,608,278
Phone650-466-7125
Websitehttps://www.alxoncology.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ALX Oncology Holdings Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
ALX Oncology Holdings Inc. Common Stock (ALXO) has returned 74.34% so far this year and 256.05% over the past 12 months. Looking at the last ten years, ALXO has achieved an annualized return of -25.32%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
ALXO
1M-10.45%
6M-11.26%
YTD74.34%
1Y256.05%
5Y-50.12%
10Y-25.32%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of ALX Oncology Holdings Inc. Common Stock (ALXO) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 53.98% | 27.11% | -0.74% | -3.43% | ||||||||
| 2025 | -14.12% | -21.99% | -42.31% | -11.49% | -8.08% | -14.82% | 35.12% | 112.73% | 61.95% | -15.38% | -12.74% | -15.04% |
| 2024 | -2.04% | 1.38% | -24.30% | 51.29% | -37.54% | -43.59% | -17.53% | -27.50% | -20.87% | -21.43% | 4.96% | 12.84% |
| 2023 | -17.11% | -29.20% | -32.94% | 29.41% | 10.07% | 11.92% | -18.53% | -29.70% | 9.84% | 50.31% | 8.59% | 92.13% |
| 2022 | -27.14% | 12.41% | -3.54% | -25.44% | -39.51% | 3.85% | 19.95% | 31.58% | -26.04% | 24.51% | -9.98% | 1.17% |
| 2021 | -8.18% | 0.36% | -8.81% | -15.81% | -11.31% | -3.80% | 6.92% | 20.79% | 4.26% | -23.89% | -42.58% | -35.04% |
| 2020 | -10.41% | 24.58% | -6.45% | 4.58% | 93.92% | 11.11% |
Performance Indicators
The charts below present risk-adjusted performance metrics for ALX Oncology Holdings Inc. Common Stock (ALXO) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of ALXO compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current ALX Oncology Holdings Inc. Common Stock volatility is 3.70%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 59.05M | 147.78M | 242.55M | 306.49M | 380.18M | 436.05M |
| Equity Attributable To Parent (USD) | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - |
| Equity (USD) | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M |
| Other Non-current Liabilities (USD) | - | 5.06M | 6.24M | 4.10M | - | - |
| Long-term Debt (USD) | 10.17M | 10.60M | 10.60M | 10.60M | - | - |
| Noncurrent Liabilities (USD) | 8.51M | 15.66M | 16.84M | 14.70M | 1.84M | 5.00K |
| Other Current Liabilities (USD) | 15.28M | 8.70M | 21.34M | 16.54M | 8.24M | 4.23M |
| Wages (USD) | 4.36M | 5.31M | 6.07M | 3.71M | 3.29M | 1.97M |
| Accounts Payable (USD) | 4.91M | 4.50M | 8.59M | 8.07M | 3.76M | 4.00K |
| Current Liabilities (USD) | 24.55M | 18.50M | 36.00M | 28.33M | 15.30M | 6.20M |
| Liabilities (USD) | 33.07M | 34.16M | 52.84M | 43.03M | 17.13M | 6.21M |
| Other Non-current Assets (USD) | 7.12M | 10.52M | 50.31M | 31.63M | 12.27M | 10.00K |
| Fixed Assets (USD) | 1.20M | 2.91M | 3.59M | 3.89M | 897.00K | 52.00K |
| Noncurrent Assets (USD) | 8.32M | 13.42M | 53.89M | 35.52M | 13.16M | 62.00K |
| Other Current Assets (USD) | 49.66M | 133.01M | - | - | - | - |
| Prepaid Expenses (USD) | 1.07M | 1.34M | - | - | - | - |
| Current Assets (USD) | 50.73M | 134.35M | 188.66M | 270.97M | 367.02M | 435.99M |
| Assets (USD) | 59.05M | 147.78M | 242.55M | 306.49M | 380.18M | 436.05M |
News and Insights
ALX Oncology announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, with CEO Jason Lettmann and CMO Barbara Klencke delivering a corporate presentation on January 15, 2026. The clinical-stage biotech company is advancing evorpacept, a CD47-inhibitor being evaluated across multiple cancer indications, and ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 trials.
ALX Oncology reported impressive results from a Phase 2 trial combining evorpacept with rituximab and lenalidomide in treating indolent non-Hodgkin lymphoma, achieving a 92% complete response rate and 100% overall response rate.
The HER2-positive gastric cancer market is experiencing sustained growth, with over 20 companies developing novel targeted therapies, driven by advances in precision medicine and expanded HER2 testing.
ALX Oncology will participate in two healthcare conferences in November and December 2025, presenting their ongoing clinical-stage cancer therapies, including lead candidate evorpacept and new pipeline candidate ALX2004.
Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.
The gastric cancer treatment market is expected to grow positively by 2034, driven by advances in targeted therapies and immunotherapies, with emerging drugs from multiple pharmaceutical companies showing promise in treating HER2-positive and advanced gastric cancers.
ALX Oncology announced it will host a webcast event on May 20, 2025, to provide an update on its investigational antibody-drug conjugate ALX2004, which is designed to treat EGFR-expressing tumors.
The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.
ALX Oncology announced that the updated results from its Phase 2 ASPEN-06 clinical trial of evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel for the treatment of HER2-positive gastric/gastroesophageal junction cancer will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.